top of page

Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. 

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery. 
Biofit Europe 2020
TechTour Europe Future 2022 Award Winner

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022

EIT Health Catapult Biotech pitching competition Finalist StemSight

Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023


About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.

Latest news


StemSight hosts Rare Corneal Disorders Symposium in Tampere

StemSight is proud to present the first Rare Corneal Disorders Symposium to be hosted on 14th of February in Tampere University Arvo building at 3-5 pm. The symposium will present current status of corneal research from the Tampere ophthalmology community and a special patient case in KID-syndrome-associated LSCD. The event is open to the public, and will be held in Finnish.


StemSight and ERS Genomics sign CRISPR/Cas9 license agreement

The agreement with ERS Genomics grants StemSight access to the Dr Emmanuelle Charpentier's foundational patents on the CRISPR/Cas9 "gene scissors".


StemSight attends BioCapital Europe

Our CEO Laura will be attending the BioCapital Europe conference in Amsterdam on 7th-8th February. The premier European life science conference is hosted by EQT Life Science.


StemSight in San Francisco for JPM week 2024

We're kicking off 2024 by going to the world's biggest healthcare investment event, JP Morgan in San Francisco. Our CEO, Dr Laura Koivusalo will be onsite from 7th to 10th January.

Investor presentation

We are in discussions with international biotech and life science investors and corporates to get our life-changing products to first patients.



Want to know more?

Interested to join our next investment round?

Want to hear about our latest developments?

Just thought of someone we absolutely need to meet?


Send us a message!

Supported by:

Voima Ventures
Stephen Industries
Business Finland
Spark Finland
Avoihoidon Tutkimussäätiö

Co-funded by:

European Union
Leverage from the EU 2014-2020
bottom of page